Thymosin Alpha-1
Thymosin Alpha-1 (TA1) is a lab-made copy of a 28-amino-acid peptide that the thymus gland makes naturally. It is studied mostly in people as an immune treatment, and is approved in more than 35 countries for chronic hepatitis B, chronic hepatitis C and as an add-on in cancer care.
At a glance
- TA1
- Peptide
- subcutaneous
- Not yet audited here; the reference library calls it clinical
- 1.6 mg per Peptide Dosing Protocols. All 4 sources
- 10 mg in 2 mL
How much to draw
Full calculator →Opened on 1.6 mg, the figure Peptide Dosing Protocols reports for Thymosin Alpha-1, and a 10 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Thymosin Alpha-1 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 1.5 mg SC twice weekly, or 450-900 mcg daily | twice weekly, or daily4-12 weeks · Repeat course per provider direction | subcutaneous | Commonly published practitioner dosing range - provider confirmation required. |
| 1.6 mg | Twice weekly (standard); daily during chemotherapy | subcutaneous or oral | Peptide Protocol Wiki |
| Standard: 1.6 mg | Twice weekly6 to 12 months · 12 weeks Community-derived, not from a clinical trial These durations are reported from research, not personal-use recommendations. | Subcutaneous | Peptide Dosing ProtocolsWhat it saysHideHalf-life: half-life of about 2-3 hours. The standard dosing for TA1 is 1.6 mg subcutaneously twice weekly. |
| Cycling reference for immune support: 6-12 weeks on, 6 weeks off. | not statedOn-cycle 6-12 weeks, off-cycle 6 weeks | subcutaneous | Peptide Therapy Reference TextWhat it saysHideAug 2026), secondary reference; provider confirmation required. |
- twice weekly, or daily4-12 weeks · Repeat course per provider direction
- subcutaneous
- Commonly published practitioner dosing range - provider confirmation required.
- Twice weekly (standard); daily during chemotherapy
- subcutaneous or oral
- Peptide Protocol Wiki
- Twice weekly6 to 12 months · 12 weeks Community-derived, not from a clinical trial These durations are reported from research, not personal-use recommendations.
- Subcutaneous
- Peptide Dosing Protocols
What it saysHide
Half-life: half-life of about 2-3 hours. The standard dosing for TA1 is 1.6 mg subcutaneously twice weekly.
- not statedOn-cycle 6-12 weeks, off-cycle 6 weeks
- subcutaneous
- Peptide Therapy Reference Text
What it saysHide
Aug 2026), secondary reference; provider confirmation required.
- Commonly 5 mg or 10 mg vials · Reconstitute with sterile/bacteriostatic water
- Sterile water
- 2 mL bacteriostatic water
Switching categories completely, because peptides are not all tissue repair. Some of the most-studied ones are about your immune system.
We have not published an audit on Thymosin Alpha-1. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Thymosin Alpha-1 appears to help the immune system train and coordinate the cells that fight viruses and other infections. Researchers link this to stronger cell-mediated immunity, meaning more active T-cells, the cells that find and clear virus-infected and tumor cells. The strength of the evidence varies a lot by use: hepatitis B trials support it, a large 2025 sepsis trial found no significant difference in 28-day deaths, and trials in healthy adults for anti-aging goals are limited.
Potential T-cell and immune signaling modulation.
Reported side effects
Seen in studies: across more than 3,000 patients in published trials, no clinically significant adverse reaction was directly tied to the peptide. Mild redness, soreness or swelling where it is injected is common and clears within hours. In hepatitis B and C use, a temporary rise in ALT, a liver enzyme, to 2x baseline can occur. Mild tiredness and flu-like symptoms are occasional, headache is rare, and joint pain with hand swelling or an allergic reaction is very rare.
Reported by users: mild stomach upset in a minority of users.
Not ruled out: added effects when it is used alongside other drugs that change immune activity, such as immunosuppressants or biologics, which the source calls theoretically possible. In the US it is a research-use product, and purity and content can vary from vial to vial.
Who should avoid it
Organ transplant recipients on anti-rejection drugs: TA1 boosts the same arm of the immune system those drugs are trying to quiet, so it could undermine the medication or trigger rejection.
People in an active autoimmune flare: because it makes T-cells more active, it could in theory make an ongoing autoimmune attack worse. Some clinical reports suggest stable, well-controlled patients tolerate it.
Pregnant or breastfeeding women: human safety data are limited. Animal studies have not shown harm to the fetus, but the Zadaxin label rates it Category C.
People under 18: safety in children has not been established in published trials.
People with a known hypersensitivity to TA1, thymalfasin or any vial component: allergic reactions are very rare and have been limited to people with known peptide sensitivities.
What gets monitored
ALT levels should be monitored during therapy, especially in HBV/HCV use. (reported by Peptide Dosing Protocols)
Common questions
What is Thymosin Alpha-1 used for?
Its synthetic form, thymalfasin, is approved in more than 35 countries for chronic hepatitis B, chronic hepatitis C and as an immune add-on in cancer care. The strength of the evidence varies sharply by use. Trials in healthy adults for general immune support or anti-aging are limited.
What is the standard Thymosin Alpha-1 dose?
Reported amounts and schedules for Thymosin Alpha-1 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
How is Thymosin Alpha-1 reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Is Thymosin Alpha-1 FDA-approved?
No, it is not FDA-approved in the United States, where it is a research-use product. The synthetic version, thymalfasin, is sold as Zadaxin and is approved in more than 35 countries.
Did the 2025 BMJ TESTS trial prove TA1 works for sepsis?
No. The trial followed 1,106 adults at 22 Chinese centers, and its main measure, death from any cause within 28 days, was not significantly different from placebo. A 2025 meta-analysis of 11 trials reported a pooled odds ratio of 0.73, but its authors flagged caveats and said the result is not yet definitive.
What are the side effects of Thymosin Alpha-1?
Reported side effects are mild and usually pass on their own. The most common are redness or soreness where it is injected and, in hepatitis use, a temporary rise in the liver enzyme ALT. Tiredness and flu-like symptoms are occasional, and across more than 3,000 trial patients no clinically significant adverse reaction was directly tied to the peptide.
Who should not use Thymosin Alpha-1?
The source lists organ transplant recipients on anti-rejection drugs and people with a known hypersensitivity to it. It also lists people in an active autoimmune flare, pregnant or breastfeeding women, and anyone under 18. The common reason is that TA1 activates the immune system, or that safety data for the group are limited.
Is Thymosin Alpha-1 the same as TB-500?
No. The reference library describes them as different peptides with distinct functions.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.
Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.
LL-37 is the active 37-amino-acid piece of the only known human cathelicidin, a natural germ-fighting protein made by white blood cells, skin cells and other tissue linings. It is studied in antimicrobial and innate-immunity research.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.